tiprankstipranks
The Fly

Keros Therapeutics price target lowered to $23 from $63 at Oppenheimer

Keros Therapeutics price target lowered to $23 from $63 at Oppenheimer

Oppenheimer lowered the firm’s price target on Keros Therapeutics (KROS) to $23 from $63 and keeps an Outperform rating on the shares after the company announced it voluntarily terminated Phase 2 TROPOS study of cibotercept/PAH following new observations of pericardial effusions. The company still plans to share full results from TROPOS in Q2 2025, informing the nature of PEs, treatment duration, exposure, and any benefit from cibotercept.

Discover the Best Stocks and Maximize Your Portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1